Tumor regression by repeated intratumoral delivery of water soluble lipopolymers/p2CMVmIL-12 complexes

Journal of Controlled Release

Volumn 87, Issue 1-3, 2003, Pages 177-186

  Yockman, James W ^a   Maheshwari, Anurag ^a   Han, Sang oh ^a   Kim, Sung Wan ^a  

^a UNIVERSITY OF UTAH   (United States)

Author keywords

Gene therapy; Interleukin 12; Intratumoral biodistribution; Tumor regression; Water soluble lipopolymer

Indexed keywords

4 [3 (3 METHYL 2(3H) BENZOTHIAZOLYLIDENE) 1 PROPENYL] 1 [3 (TRIMETHYLAMMONIO)PROPYL]DIIODIDE; INTERLEUKIN 12; POLYMER; THIAZOLE DERIVATIVE; UNCLASSIFIED DRUG; WATER SOLUBLE LIPOPOLYMER INTERLEUKIN 12 COMPLEX;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; CANCER CELL CULTURE; CANCER INHIBITION; COLON ADENOCARCINOMA; COMPLEX FORMATION; CONFERENCE PAPER; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; FEMALE; GENE EXPRESSION; IN VIVO STUDY; MOUSE; NONHUMAN; ORGAN DISTRIBUTION; PRIORITY JOURNAL; TRANSGENE; TUMOR REGRESSION;

ANIMALS; CELL SURVIVAL; CYTOMEGALOVIRUS; DRUG DELIVERY SYSTEMS; FEMALE; INJECTIONS, INTRALESIONAL; INTERLEUKIN-12; LIPIDS; MICE; MICE, INBRED BALB C; PLASMIDS; POLYMERS; SOLUBILITY; TUMOR CELLS, CULTURED; WATER; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0037458828     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-3659(02)00362-0     Document Type: Article

References (41)

1. Halin C., Rondini S., Nilsson F., Berndt A., Kosmehl H., Zardi L., Neri D. Enhancement of the antitumor activity of interleukin-12 by targeted delivery to neovasculature. Nature Biotechnol. 20:2002;264-269.
2. Mattes M.J. Radionuclide-antibody conjugates for single-cell cytotoxicity. Cancer. 94:2002;1215-1223.
3. Shaw D., Berger F.G., Spencer H.T. Retroviral expression of Escherichia coli thymidylate synthase cDNA confers high-level antifolate resistance to hematopoietic cells. Hum. Gene Ther. 12:2001;51-59.
4. Patel M., Sleep S.E., Lewis W.S., Spencer H.T., Mareya S.M., Sorrentino B.P., Blakley R.L. Comparison of the protection of cells from antifolates by transduced human dihydrofolate reductase mutants. Hum. Gene Ther. 8:1997;2069-2077.
5. Schatzlein A.G. Non-viral vectors in cancer gene therapy: principles and progress. Anticancer Drugs. 12:2001;275-304.
6. Tahara H., Zitvogel L., Storkus W.J., Robbins P.D., Lotze M.T. Murine models of cancer cytokine gene therapy using interleukin-12. Ann. NY Acad. Sci. 795:1996;275-283.
7. Lode H.N., Xiang R., Duncan S.R., Theofilopoulos A.N., Gillies S.D., Reisfeld R.A. Tumor-targeted IL-2 amplifies T cell-mediated immune response induced by gene therapy with single-chain IL-12. Proc. Natl. Acad. Sci. USA. 96:1999;8591-8596.
8. Hendrzak J.A., Brunda M.J. Antitumor and antimetastatic activity of interleukin-12. Curr. Top. Microbiol. Immunol. 213:(3):1996;65-83.
9. Addison C.L., Bramson J.L., Hitt M.M., Muller W.J., Gauldie J., Graham F.L. Intratumoral coinjection of adenoviral vectors expressing IL-2 and IL-12 results in enhanced frequency of regression of injected and untreated distal tumors. Gene Ther. 5:1998;1400-1409.
10. Xiang R., Lode H.N., Gillies S.D., Reisfeld R.A. T cell memory against colon carcinoma is long-lived in the absence of antigen. J. Immunol. 163:1999;3676-3683.
11. Tanaka M., Saijo Y., Sato G., Suzuki T., Tazawa R., Satoh K., Nukiwa T. Induction of antitumor immunity by combined immunogene therapy using IL-2 and IL-12 in low antigenic Lewis lung carcinoma. Cancer Gene Ther. 7:2000;1481-1490.
12. Leonard J.P., Sherman M.L., Fisher G.L., Buchanan L.J., Larsen G., Atkins M.B., Sosman J.A., Dutcher J.P., Vogelzang N.J., Ryan J.L. Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production. Blood. 90:1997;2541-2548.
13. Brunda M.J., Luistro L., Warrier R.R., Wright R.B., Hubbard B.R., Murphy M., Wolf S.F., Gately M.K. Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J. Exp. Med. 178:1993;1223-1230.
14. Rakhmilevich A.L., Timmins J.G., Janssen K., Pohlmann E.L., Sheehy M.J., Yang N.S. Gene gun-mediated IL-12 gene therapy induces antitumor effects in the absence of toxicity: a direct comparison with systemic IL-12 protein therapy. J. Immunother. 22:1999;135-144.
15. Caruso M., Pham-Nguyen K., Kwong Y.L., Xu B., Kosai K.I., Finegold M., Woo S.L., Chen S.H. Adenovirus-mediated interleukin-12 gene therapy for metastatic colon carcinoma. Proc. Natl. Acad. Sci. USA. 93:1996;11302-11306.
16. Lohr F., Lo D.Y., Zaharoff D.A., Hu K., Zhang X., Li Y., Zhao Y., Dewhirst M.W., Yuan F., Li C.Y. Effective tumor therapy with plasmid-encoded cytokines combined with in vivo electroporation. Cancer Res. 61:2001;3281-3284.
17. Yamashita Y.I., Shimada M., Hasegawa H., Minagawa R., Rikimaru T., Hamatsu T., Tanaka S., Shirabe K., Miyazaki J.I., Sugimachi K. Electroporation-mediated interleukin-12 gene therapy for hepatocellular carcinoma in the mice model. Cancer Res. 61:2001;1005-1012.
18. Whitmore M., Li S., Huang L. LPD lipopolyplex initiates a potent cytokine response and inhibits tumor growth. Gene Ther. 6:1999;1867-1875.
19. Dow S.W., Elmslie R.E., Fradkin L.G., Liggitt D.H., Heath T.D., Willson A.P., Potter T.A. Intravenous cytokine gene delivery by lipid-DNA complexes controls the growth of established lung metastases. Hum. Gene Ther. 10:1999;2961-2972.
20. Boussif O., Lezoualc'h F., Zanta M.A., Mergny M.D., Scherman D., Demeneix B., Behr J.P. A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc. Natl. Acad. Sci. USA. 92:1995;7297-7301.
21. Abdallah B., Hassan A., Benoist C., Goula D., Behr J.P., Demeneix B.A. A powerful nonviral vector for in vivo gene transfer into the adult mammalian brain: polyethylenimine. Hum. Gene Ther. 7:1996;1947-1954.
22. Han S., Mahato R.I., Kim S.W. Water-soluble lipopolymer for gene delivery. Bioconjug. Chem. 12:2001;337-345.
23. Mahato R.I., Lee M., Han S., Maheshwari A., Kim S.W. Intratumoral delivery of p2CMVmIL-12 using water-soluble lipopolymers. Mol. Ther. 4:2001;130-138.
24. Tannenbaum C.S., Wicker N., Armstrong D., Tubbs R., Finke J., Bukowski R.M., Hamilton T.A. Cytokine and chemokine expression in tumors of mice receiving systemic therapy with IL-12. J. Immunol. 156:1996;693-699.
25. Oshikawa K., Rakhmilevich A.L., Shi F., Sondel P.M., Yang N., Mahvi D.M. Interleukin 12 gene transfer into skin distant from the tumor site elicits antimetastatic effects equivalent to local gene transfer. Hum. Gene Ther. 12:2001;149-160.
26. Fujiwara H., Hamaoka T. The anti-tumor effects of IL-12 involve enhanced IFN-gamma production by anti-tumor T cells, their accumulation to tumor sites and in situ IFN-gamma production. Leukemia. 11:(Suppl. 3):1997;570-571.
27. Bree A.G., Schlerman F.J., Kaviani M.D., Hastings R.C., Hitz S.L., Goldman S.J. Multiple effects on peripheral hematology following administration of recombinant human interleukin 12 to nonhuman primates. Biochem. Biophys. Res. Commun. 204:1994;1150-1157.
28. Cohen J. IL-12 deaths: explanation and a puzzle. Science. 270:1995;908.
29. Sarmiento U.M., Riley J.H., Knaack P.A., Lipman J.M., Becker J.M., Gately M.K., Chizzonite R., Anderson T.D. Biologic effects of recombinant human interleukin-12 in squirrel monkeys (Sciureus saimiri). Lab. Invest. 71:1994;862-873.
30. Lohr F., Huang Q., Hu K., Dewhirst M.W., Li C.Y. Systemic vector leakage and transgene expression by intratumorally injected recombinant adenovirus vectors. Clin. Cancer Res. 7:2001;3625-3628.
31. Smyth M.J., Taniguchi M., Street S.E. The anti-tumor activity of IL-12: mechanisms of innate immunity that are model and dose dependent. J. Immunol. 165:2000;2665-2670.
32. Kang W.K., Park C., Yoon H.L., Kim W.S., Yoon S.S., Lee M.H., Park K., Kim K., Jeong H.S., Kim J.A., Nam S.J., Yang J.H., Son Y.I., Baek C.H., Han J., Ree H.J., Lee E.S., Kim S.H., Kim D.W., Ahn Y.C., Huh S.J., Choe Y.H., Lee J.H., Park M.H., Kong G.S., Park E.Y., Kang Y.K., Bang Y.J., Paik N.S., Lee S.N., Kim S., Robbins P.D., Tahara H., Lotze M.T., Park C.H. Interleukin 12 gene therapy of cancer by peritumoral injection of transduced autologous fibroblasts: outcome of a phase I study. Hum. Gene Ther. 12:2001;671-684.
33. Tousignant J.D., Gates A.L., Ingram L.A., Johnson C.L., Nietupski J.B., Cheng S.H., Eastman S.J., Scheule R.K. Comprehensive analysis of the acute toxicities induced by systemic administration of cationic lipid:plasmid DNA complexes in mice. Hum. Gene Ther. 11:2000;2493-2513.
34. Nomura T., Koreeda N., Yamashita F., Takakura Y., Hashida M. Effect of particle size and charge on the disposition of lipid carriers after intratumoral injection into tissue-isolated tumors. Pharm. Res. 15:1998;128-132.
35. Zuhorn I.S., Kalicharan R., Hoekstra D. Lipoplex-mediated transfection of mammalian cells occurs through the cholesterol-dependent clathrin-mediated pathway of endocytosis. J. Biol. Chem. 277:2002;18021-18028.
36. Nomura T., Nakajima S., Kawabata K., Yamashita F., Takakura Y., Hashida M. Intratumoral pharmacokinetics and in vivo gene expression of naked plasmid DNA and its cationic liposome complexes after direct gene transfer. Cancer Res. 57:1997;2681-2686.
37. Benns J.M., Maheshwari A., Furgeson D.Y., Mahato R.I., Kim S.W. Folate-PEG-folate-graft-polyethylenimine-based gene delivery. J. Drug Target. 9:2001;123-139.
38. Takakura Y., Nishikawa M., Yamashita F., Hashida M. Development of gene drug delivery systems based on pharmacokinetic studies. Eur. J. Pharm. Sci. 13:2001;71-76.
39. Rakhmilevich A.L., Turner J., Ford M.J., McCabe D., Sun W.H., Sondel P.M., Grota K., Yang N.S. Gene gun-mediated skin transfection with interleukin 12 gene results in regression of established primary and metastatic murine tumors. Proc. Natl. Acad. Sci. USA. 93:1996;6291-6296.
40. Smyth M.J., Thia K.Y., Street S.E., Cretney E., Trapani J.A., Taniguchi M., Kawano T., Pelikan S.B., Crowe N.Y., Godfrey D.I. Differential tumor surveillance by natural killer (NK) and NKT cells. J. Exp. Med. 191:2000;661-668.
41. Colombo M.P., Vagliani M., Spreafico F., Parenza M., Chiodoni C., Melani C., Stoppacciaro A. Amount of interleukin 12 available at the tumor site is critical for tumor regression. Cancer Res. 56:1996;2531-2534.